Monoclonal Gammopathy of Renal Significance
📧 Sign up to get email alerts when something new happens for Monoclonal Gammopathy of Renal Significance.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) [Phase 2]
A Phase 2 study evaluating CyBorD (cyclophosphamide, bortezomib, dexamethasone) plus daratumumab in people with Monoclonal Gammopathy of Ren…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance [Phase 2]
Phase 2 clinical trial evaluating isatuximab in patients with monoclonal gammopathy of renal significance is currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland [Phase 2]
Phase 2 clinical trial evaluating daratumumab for monoclonal gammopathy of renal significance (MGRS) in Finland; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD [Phase 2]
A Phase 2 clinical trial is evaluating a quadruple regimen of daratumumab, bortezomib, cyclophosphamide, and dexamethasone for Monoclonal Ga…